Prognostic Impact of FLT3‐ITD Microclones in AML: An EHA AML‐Specialized Working Group StudyCarmelo Gurnari,
Tiziana Ottone,
Alfonso Piciocchi,
Daniela Späth,
Annika Meid,
Giovanni Marsili,
Emiliano Fabiani,
Francesca Romano,
Maria Rosaria Pascale,
Paola Ricci,
Patrizia Chiusolo,
Mauro Di Ianni,
Marta Sobas,
Lorenzo Brunetti,
Guadalupe Oñate,
Joana Brioso Infante,
Jacopo Nanni,
Calogero Vetro,
Matilde Boada,
Anna Candoni,
Jorge Sierra,
Nicola Potter,
Amanda Gilkes,
Sean James Johnson,
Ian Thomas,
Brian Huntly,
Adriano Venditti,
Nigel Russell,
Richard Dillon,American Journal of Hematology
· Hematology
· 2026-11-02
ABSTRACT The 2022 ELN recommendations reclassified fms‐like tyrosine kinase‐3 ( FLT3 )‐ITD mutated acute myeloid leukemia (AML) as intermediate‐risk, irrespective of allelic ratio (AR), and designated capillary electrophoresis (CE) as...
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematologic disorder characterized by complement‐mediated intravascular hemolysis, pancytopenia, and thrombosis. NTQ5082 is a novel oral selective complement factor B (CFB)...
Clinical Experience of Iptacopan in Paroxysmal Nocturnal HemoglobinuriaMatthew Holt,
Richard J. Kelly,
Regis Peffault de Latour,
Morag Griffin,
Shreyans Gandhi,
Edouard Forcade,
Francesco Versino,
Roochi Trikha,
Alexandra Pike,
Joanna Large,
Michael Loschi,
Marc Michel,
Petra Muus,
Talha Munir,
Alice Garnier,
Simona Pagliuca,
Yosr Hicheri,
Isabelle Brindel,
Sateesh Nagumantry,
Lynda Maafa,
Louise M. Arnold,
Austin Kulasekararaj,
Flore Sicre de FontbruneAmerican Journal of Hematology
· Hematology
· 2026-10-28
ABSTRACT Iptacopan, an oral Factor B inhibitor, is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In clinical trials it was safe and effective but real‐world data, particularly in patients with associated bone...
ABSTRACT Hexokinase 1 (HK1) deficiency is a rare cause of hereditary nonspherocytic hemolytic anemia characterized by impaired erythrocyte glycolysis, but its broader molecular consequences of HK1 dysfunction remain poorly understood....
Prognostic Impact of FLT3‐ITD Allelic Ratio in AML Patients Treated With High‐Dose Anthracycline and a FLT3 InhibitorMathieu Leclerc,
Etienne Audureau,
Nicolas Duployez,
Mathilde Hunault,
Emmanuelle Tavernier,
Cécile Pautas,
Sarah Bertoli,
Emmanuel Raffoux,
Marie‐Anne Hospital,
Tony Marchand,
Maël Heiblig,
Sylvain Chantepie,
Martin Carre,
Pierre Peterlin,
Maria‐Pilar Gallego‐Hernanz,
Romain Guieze,
Célestine Simand,
Pascal Turlure,
Anne Huynh,
Emilie Lemasle,
Ludovic Gabellier,
Juliette Lambert,
Felipe Suarez,
Samy Chraibi,
Laurence Sanhes,
Karine Celli‐Lebras,
Ariane Mineur,
Claude American Journal of Hematology
· Hematology
· 2026-10-27
ABSTRACT The prognostic value of FLT3 internal tandem duplication ( FLT3 ‐ITD) in acute myeloid leukemia (AML) has traditionally been stratified according to the ITD/wild‐type allelic ratio (AR) and NPM1 co‐mutation status. We evaluated...
ABSTRACT Janus kinase inhibitors are the cornerstone of treatment for myelofibrosis, but have limited disease‐modifying activity. Combinations of ruxolitinib with pelabresib, navitoclax, or selinexor improve spleen responses, although...
ABSTRACT In AL amyloidosis, advanced renal disease can impact treatment options and cause significant morbidity. Patients with ESRD requiring dialysis are a group with currently unmet needs. In this collaborative study, we identified...
Plasma Exchange and Daratumumab for Myeloma Cast NephropathyChristina I. Shincovich,
Api Chewcharat,
Motohiko Adomi,
Emma E. McGee,
Raphael Kim,
Marta Pirovano,
Jason Prosek,
Srinivas S. Devarakonda,
Joshua Leisring,
Eshetu Obole,
Jasmin Tharakan,
Arti Vaishnav,
Nattawat Klomjit,
Pornlada Likasitwatanakul,
Chester Andrzejewski,
Sajjad Hassan,
Annie Elizabeth Abraham,
Lynne O'Hearn,
Oscar Garcia Valencia,
Jennifer S. McDonald,
M. Salman Sheikh,
Boyoung Michelle Kim,
Priscilla Koirala,
A. Bilal Malik,
Anip Bansal,
Blaithin A. McMahAmerican Journal of Hematology
· Hematology
· 2026-10-13
ABSTRACT Multiple myeloma light chain cast nephropathy (LCCN) is often treated with plasma exchange (PLEX) or the anti‐CD38 monoclonal antibody, daratumumab. However, rigorous studies supporting these therapies for LCCN are limited....
ABSTRACT Terminal erythroid differentiation involves dramatic cellular remodeling that culminates in the expulsion of the nucleus, a process known as enucleation. While enucleation is conserved across mammals and is crucial for the...
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the...
ABSTRACT Nodal T‐follicular helper cell lymphoma (nTFHL), most commonly of angioimmunoblastic type, exhibits heterogeneous clinical outcomes that are not fully explained by current clinical and biological variables. While genetic...